You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance
Assessment of the cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and extent of the COVID-19 epidemic. Here, we report estimated seroprevalence in the French population and the proportion of infected individuals who developed neutralising antibodies at three points throughout the first epidemic wave. Testing 11,000 residual specimens for anti-SARS-CoV-2 IgG and neutralising antibodies, we find nationwide seroprevalence of 0.41% (95% CI: 0.05–0.88) mid-March, 4.14% (95% CI: 3.31–4.99) mid-April and 4.93% (95% CI: 4.02–5.89) mid-May 2020. Approximately 70% of seropositive individuals have detectable neutralising antibodies. Infection fatality rate is 0.84% (95% CI: 0.70–1.03) and increases exponentially with age. These results confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remained susceptible to SARS-CoV-2 in May 2020. Our study shows the progression of the first epidemic wave and provides a framework to inform the ongoing public health response as viral transmission continues globally.
The percentage of national populations infected during the first stages of the COVID-19 pandemic are unclear owing to limited early testing. Here the authors provide a nation-wide prevalence study of SARS-CoV-2 antibodies in France from the first wave of COVID-19 in 2020, including stratification based on age, sex and region.
- Université Paris Diderot France
- Institut Pasteur France
- Inserm France
Microsoft Academic Graph classification: Serology Case fatality rate Cumulative incidence education.field_of_study biology Transmission (medicine) medicine.symptom Antibody medicine.medical_specialty Population Asymptomatic medicine Seroprevalence education business.industry Public health Seroepidemiologic Studies biology.protein business Demography
Male, Epidemiology, [SDV]Life Sciences [q-bio], General Physics and Astronomy, Antibodies, Viral, Seroepidemiologic Studies, Prevalence, Child, Aged, 80 and over, Multidisciplinary, Q, Middle Aged, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Child, Preschool, Female, France, Adult, Adolescent, Science, General Biochemistry, Genetics and Molecular Biology, Article, Young Adult, Humans, Epidemics, Aged, SARS-CoV-2, Infant, Newborn, COVID-19, Infant, General Chemistry, Viral infection, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Male, Epidemiology, [SDV]Life Sciences [q-bio], General Physics and Astronomy, Antibodies, Viral, Seroepidemiologic Studies, Prevalence, Child, Aged, 80 and over, Multidisciplinary, Q, Middle Aged, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Child, Preschool, Female, France, Adult, Adolescent, Science, General Biochemistry, Genetics and Molecular Biology, Article, Young Adult, Humans, Epidemics, Aged, SARS-CoV-2, Infant, Newborn, COVID-19, Infant, General Chemistry, Viral infection, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Microsoft Academic Graph classification: Serology Case fatality rate Cumulative incidence education.field_of_study biology Transmission (medicine) medicine.symptom Antibody medicine.medical_specialty Population Asymptomatic medicine Seroprevalence education business.industry Public health Seroepidemiologic Studies biology.protein business Demography
27 references, page 1 of 3
1 Bernard Stoecklin S, Rolland P, Silue Y, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill 2020; 25. DOI:10.2807/1560-7917.Es.2020.25.6.2000094.
2 Carrat F, de Lamballerie X, Rahib D, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study. medRxiv 2020; : 2020.09.16.20195693.
3 Payne DC, Smith-Jeffcoat SE, Nowak G, et al. SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members - USS Theodore Roosevelt, April 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 714-21.
4 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet 2020. DOI:10.1016/s0140-6736(20)31483-5.
5 Ward H, Atchison CJ, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. medRxiv 2020; : 2020.08.12.20173690.
6 Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 - Studies Needed. N Engl J Med 2020; 382: 1194-6.
7 Aziz NA, Corman VM, Echterhoff AKC, et al. Seroprevalence and correlates of SARSCoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany. medRxiv 2020; : 2020.08.24.20181206.
8 ROEDERER T, MOLLO B, VINCENT C, et al. High seroprevalence of SARS-CoV-2 antibodies among people living in precarious situations in Ile de France. medRxiv 2020; : 2020.10.07.20207795.
9 Skowronski DM, Sekirov I, Sabaiduc S, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020. medRxiv 2020; : 2020.07.13.20153148.
10Thompson C, Grayson N, Paton R, et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure. medRxiv 2020; : 2020.04.13.20060467.
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).71 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1% citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).71 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1% Powered byBIP!